Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9H3M9

UPID:
ATX3L_HUMAN

ALTERNATIVE NAMES:
Machado-Joseph disease protein 1-like

ALTERNATIVE UPACC:
Q9H3M9; B2RNY8

BACKGROUND:
The Ataxin-3-like protein, alternatively known as Machado-Joseph disease protein 1-like, functions as a deubiquitinating enzyme. It is distinguished by its capacity to cleave 'Lys-48'-linked and 'Lys-63'-linked poly-ubiquitin chains, indicating its significant role in the ubiquitin-proteasome system.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Ataxin-3-like protein holds promise for uncovering new therapeutic avenues. Its critical role in modulating ubiquitin chains positions it as a potential target in the development of treatments for diseases linked to protein degradation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.